Sintx Technologies Business Summary

Sintx Technologies, Inc. (SINT) is a vertically integrated advanced ceramics company specializing in the research, development, and commercialization of medical-grade silicon nitride (Si3N4). The company generates revenue through a multi-channel model encompassing the sale of proprietary spinal and orthopedic implants, the supply of advanced ceramic powders, and private-label manufacturing agreements, such as the OsseoSculpt biologic line. Its operations are divided into three primary segments: Biomedical, which targets the $62 billion orthopedic and dental markets; Technical, providing high-performance components for aerospace and industrial applications; and Antipathogenic, which leverages the material's antimicrobial properties for medical textiles and PPE. Sintx competes with medical equipment and material firms such as Nephros (NEPH), NeurAxis (NRXS), and CeramTec. As the only FDA-registered producer of implantable silicon nitride, Sintx occupies a specialized niche, positioning itself as a high-tech biomaterials leader with a unique competitive moat in material-specific intellectual property and additive manufacturing. Originally founded in 1996 as Amedica Corporation by material scientist Dr. Ashok Khandkar and orthopedic surgeon Dr. Sonny Bal, the company is currently led by Chairman and CEO Eric K. Olson. Olson is a serial entrepreneur who previously served as the company’s CEO during its 2014 IPO and returned in 2024 to spearhead a strategic recapitalization and the 2025 acquisition of SiNAPTIC Surgical. The executive team includes CTO Dr. Ryan Bock, a ceramic science expert with over 20 years of R&D experience, and Chief Investment Officer Gregg R. Honigblum, a veteran investment banker who has facilitated over $100 million in private equity for the firm. Commercial operations are directed by Chief Commercial Officer Lisa Marie Del Re, a MedTech veteran with 15 years of market expansion expertise, alongside CFO Donald Trask. The Board of Directors features prominent industry figures, including Lead Independent Director Jay M. Moyes (former CFO of Myriad Genetics), Mark Anderson (formerly of Boston Scientific), and Chris Lyons (formerly of Medtronic), with institutional support from investors such as Anson Funds Management and Veracity Capital.